|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Systemic contact dermatitis from nickel associated with orthodontic appliances显示文摘 | Pigatto PD Guzzi G | 2004 | Contact Dermatitis2004，50，2： | 1 |
| 2 | Efficacy and safety of Avene Thermal Sprng water in the healingof facial skin after laser resurfacing显示文摘 | Sulimovic L Licu D Ledo E Naeyaert JM Pigatto P Tzermias C Vasquez Doval J Dupuy P | 2002 | Dermatol Surg2002，28，5： | 1 |
| 3 | Evaluation of right ventricular function performed by 3D-echocardiography in scleroderma patients显示文摘 | Pigatto E Peluso D Zanatta E | 2015 | Reumatismo2015，66，4： | 1 |
| 4 | Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents显示文摘AIM To evaluate the outcomes in biological treatment and quality of life of psoriatic patients with chronic hepatitis C(CHC) treated with new Direct-Acting Antiviral agents(DAAs) compared to pegylated interferon-2α plus ribavirin(P/R) therapy.METHODS This is a retrospective study involving psoriatic patients in biological therapy who underwent anti-hepatitis C virus(HCV) treatment at the Department of Dermatology Galeazzi Orthopaedic Institute Milan, Italy from January 2010 to November 2017. The patients were divided into two groups: patients that underwent therapy with DAAs and patients that underwent HCV treatment with P/R. Patients were assessed by a dermatologist for psoriasis symptoms, collecting Psoriasis Area Severity Index(PASI) scores and the Dermatology Quality of Life Index(DLQI). PASI and DLQI scores were evaluated 24 wk after the end of HCV treatment and were assumed as an outcome of the progression of psoriasis. Switching to a different b DMARD was considered as an inadequate response to biological therapy. The dropout of HCV therapy and sustained virological response(SVR) were considered as outcomes of HCV therapy.RESULTS Fifty-nine psoriatic patients in biological therapy underwent antiviral therapy for CHC. Of this, 27 patients were treated with DAAs and 32 with P/R. After 24 wk post treatment, the DLQI and the PASI scores were significantly lower(P < 0.001 and P < 0.005, respectively) in the DAAs group compared with P/R group. None of the patients in the DAAs group(0/27) compared to 8 patients of the P/R group(8/32) needed a shift in biological treatment.CONCLUSION DAAs seem to be more effective and safe than P/R in HCV-positive psoriatic patients on biological treatment. Fewer dermatological adverse events may be due to interferon-free therapy. | Giovanni Damiani Chiara Franchi Paolo Pigatto Andrea Altomare Alessia Pacifico Stephen Petrou Sebastiano Leone Maria Caterina Pace Marco Fiore | 2018 | World Journal of Hepatology2018，10，2： | 1 |
| 5 | Helicobacter pylori and chronic urticaria: the role of eradication 显示文摘 | Carnevale P Bierti L Pigatto P | 1998 | Gastrogenterology1998，114，1： | 1 |
| 6 | Photopatch tests: anItalian multicentre study from 2004 to 2006 显示文摘 | Pigatto PD Guzzi G Schena D | 2008 | ContactDermatitis2008，59，2： | 1 |
| 7 | Metal sensitivity in patients with orthopaedic implants: a prospective study 显示文摘 | Frigerio E Pigatto PD Guzzi G | 2011 | Contact Dermatitis2011，64，5： | 1 |
| 8 | Probiotics: immunomodulatory properties in allergy and eczema 显示文摘 | Drago L Toscano M Pigatto PD | 2013 | G hal Dermatol Venereol2013，148，5： | 1 |
| 9 | HPLC - UV method for quantifying etoposide in plasma and tumor interstitial fluid by microdialysis:application to pharmacokinetic studies显示文摘 | Pigatto M C Mossmann D L Costa T D | 2015 | Biomedical Chromatography2015，29，： | 1 |
| 10 | Management of subcutaneous implantation of mercury after broken thermometer显示文摘 | Paolo D. Pigatto Gianpaolo Guzzi | 2010 | Journal of the American Academy of Dermatology2010，，2： | 1 |
| 11 | Photopatch tests: an Italian muhieentre study from 2004 to 2006 显示文摘 | Pigatto PD Guzzi G Schena D | 2008 | Contact Dermatitis2008，59，2： | 1 |
| 12 | Photopatch tests:Italian multicentre study from 2004 to 2006显示文摘 | Pigatto PD Guzzic Schena D et a1 | 2008 | Contact Dermatitis2008，59，2： | 1 |
| 13 | Circadian rhythm of the in vivo migration ofneutrophils in psoriatic patients显示文摘 | Pigatto PD Radaelli A Tadini G | 1985 | Arch Dermatol Res1985，277，3： | 1 |
| 14 | The efficacy of Ave ne thermal spring water in light to moderate atopic dermatitis显示文摘 | Pigatto P | 2005 | Ann Dermatol Venereol2005，132，102： | 1 |
| 15 | Medium-/ long-term effects of a specific exercise protocol combined with patient education on spine mobility, chronic fatigue, pain, aerobic fitness and level of disability in fibromyalgia 显示文摘 | Giannotti E Koutsikos K Pigatto M | 2014 | Biomed Res Int2014，2014，47： | 1 |
| 16 | Study of polypropylene/ethylene-propylene-diene monomer blends reinforced with sisal fibers显示文摘 | Caroline Pigatto JoséHumberto Santos Almeida Júnior Heitor Luiz Ornaghi Júnior | 2012 | Polymer Composites2012，33，12： | 1 |
| 17 | Metal sensitivity in patients wi: orthopaedic implants:a prospective study显示文摘 | Frigerio E Pigatto P D Guaai G | 2011 | Contact Dermato12011，42，2： | 1 |
| 18 | Systemic contact dermatitis from nickel associated with orthodontic appliances 显示文摘 | Pigatto PD Guzzi G | 2004 | Contact Dermatitis2004，50，2： | 1 |
| 19 | Nanotechnology meets atopic dermatitis: Current solutions, challenges and future prospects. Insights and implications from a systematic review of the literature显示文摘Atopic dermatitis is a chronic,relapsing,non-contiguous,exudative eczema/dermatitis,which represents a complex,multi-factorial disorder,due to an impairment of the stratum corneum barrier.Currently available drugs have a low skin bioavailability and may give rise to severe adverse events.Nanotechnologies,including nanoparticles,liposomes,nano-gels,nano-mixtures,nano-emulsions and other nano-carriers,offer unprecedented solutions to these issues,enabling:i)the management of different clinical forms of atopic dermatitis,especially the recalcitrant ones,i)a better bio-availability and trans-dermal drug targeted delivery at the inflammation site,ii)dose control,iii)significant improvements both in clinical symptoms and immune responses,iv)with less adverse events being reported and a better safety profile.However,some nano-sized structures could amplify and even worsen symptoms in particularly susceptible individuals.Furthermore,most studies included in the present systematic review have been conducted in-vitro or in-vivo,with few randomized controlled clinical trials(RCTs).Future investigations should adopt this design in order to enable scholars achieving robust findings and evidence.Therefore,given the above-mentioned shortcomings,further research in the field is urgently warranted. | Giovanni Damiani Roberto Eggenhöffner Paolo Daniele Maria Pigatto Nicola Luigi Bragazzi | 2019 | Bioactive Materials2019，4，1： | 1 |
| 20 | Chronic urticaria and Helicobacter pylori 显示文摘 | Valsecchi R Pigatto P | 1998 | Acta Derm Venereol1998，78，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员